Patients receiving nirmatrelvir/ritonavir experience a quicker resolution of COVID-19 symptoms and are less likely to have worsened symptoms than those receiving placebo, a recent study shows.

Nirmatrelvir Speeds Recovery, Cuts Symptoms in COVID-19

Pfizer says it is “confident” in the intellectual property for its billion-dollar Covid-19 pill Paxlovid.

Pfizer battles another Paxlovid lawsuit from Enanta

Pharmac to update access and supply of COVID-19 treatments.

Pharmac to update access and supply of COVID-19 treatments

Hyundai Bioscience's Covid-19 treatment, Xafty, is significantly more effective than other Covid-19 drugs, according to a recent study.

Xafty outperforms Paxlovid, Xocova in Covid-19 trial, Hyundai Bioscience says

Global health leaders unite to map immune markers for epidemic viruses while NanoViricides reports breakthrough antiviral drug success against measles in preclinical trials.

CEPI PATH Develop Vaccine Playbooks NanoViricides Advances Measles Drug

Edward Weinstein, MD of Pfizer, says longer courses may benefit severely immunocompromised patients, even without major gains in viral suppression.

antiviral news

Press Releases in the global landscape

Nirmatrelvir Speeds Recovery, Cuts Symptoms in COVID-19

Pfizer battles another Paxlovid lawsuit from Enanta

Pharmac to update access and supply of COVID-19 treatments

Xafty outperforms Paxlovid, Xocova in Covid-19 trial, Hyundai Bioscience says

CEPI PATH Develop Vaccine Playbooks NanoViricides Advances Measles Drug

Extended Paxlovid Treatment Reduces Viral Rebound in Immunocompromised COVID-19 Patients